1. Signaling Pathways
  2. Cytoskeleton
  3. Integrin
  4. αvβ3 Isoform

αvβ3

 

αvβ3 Related Products (10):

Cat. No. Product Name Effect Purity
  • HY-16141
    Cilengitide
    Antagonist 99.36%
    Cilengitide (EMD 121974) is a potent integrins antagonist with IC50s of 0.61 nM (ανβ3), 8.4 nM (ανβ5) and 14.9 nM (α5β1), respectively.
  • HY-15102
    MK-0429
    Antagonist 99.84%
    MK-0429 (L-000845704) is an orally active, potent, selective and nonpeptide pan-integrin antagonist with IC50 values of 1.6 nM, 2.8 nM, 0.1 nM, 0.7 nM, 0.5 nM and 12.2 nM for αvβ1, αvβ3, αvβ5, αvβ6, αvβ8 and α5β1, respectively.
  • HY-P0023
    Cyclo(-RGDfK)
    Inhibitor ≥98.0%
    Cyclo(-RGDfK) is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM.
  • HY-100563
    Cyclo(RGDyK) trifluoroacetate
    Inhibitor 99.92%
    Cyclo(RGDyK) trifluoroacetate is a potent and selective αVβ3 integrin inhibitor with an IC50 of 20 nM.
  • HY-P0023A
    Cyclo(-RGDfK) TFA
    Inhibitor 99.82%
    Cyclo(-RGDfK) TFA is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM.
  • HY-P2300
    Cyclo(Arg-Gly-Asp-D-Phe-Cys)
    Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC) is a cyclic RGD peptide which has high affinity to αvβ3.
  • HY-P1187
    HSDVHK-NH2
    Antagonist 98.41%
    HSDVHK-NH2 is an antagonist of the integrin αvβ3-vitronectin interaction, with an IC50 of 1.74 pg/mL (2.414 pM).
  • HY-P1189A
    Echistatin TFA
    Antagonist
    Echistatin TFA, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of platelet aggregation.
  • HY-P1189
    Echistatin
    Antagonist
    Echistatin, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of platelet aggregation.
  • HY-100563A
    Cyclo(RGDyK)
    Inhibitor
    Cyclo(RGDyK) is a potent and selective αVβ3 integrin inhibitor with an IC50 of 20 nM.